Bavarian Nordic
| 220px | |
| Publicly traded Aktieselskab | |
| Traded as | OMX: BAVA |
| Industry | Biotechnology |
| Founded | 1994 |
| Headquarters | Kvistgård, Denmark, Redwood City, California and Martinsried, Germany |
|
Key people
|
Paul Chaplin (President and CEO)[1], Gerard van Odijk (Chairman)[2] |
| Products | Imvanex |
|
Number of employees
|
409 (2015)[3] |
| Website | www.bavarian-nordic.com |
Bavarian Nordic is a biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases. The company is headquartered in Kvistgaard, Denmark (a town in Helsingør Municipality), where it also operates a commercial-scale manufacturing facility. Research and development facilities are located in Redwood City, California, USA, and Martinsried, Germany.
The company uses viral vectors in its research and development.
Contents
Technologies
MVA-BN
MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells,[4] contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicating smallpox vaccine, Imvamune, it is approved in Canada[5] and in the European Union, where it is marketed as Imvanex.[6] The vaccine is being supplied for emergency use to the U.S. Strategic National Stockpile as well as other government stockpiles. Registration studies for the approval in the U.S. are currently underway.
Vaccinia-fowlpox-TRICOM
A second poxvirus-based technology is employed in most of the company’s cancer immunotherapies, and was in-licensed as part of a collaboration with the National Cancer Institute (NCI). Vaccinia-fowlpox-TRICOM is a sequential prime-boost therapy based on vaccinia and fowlpox in combination with three co-stimulatory molecules (TRICOM). The poxvirus-based immunotherapy can be modified to encode different tumor-associated antigens such as Prostate-specific antigen (PSA), Carcinoembryonic antigen (CEA) and/or Mucin 1 (MUC1), which are all tumor markers that are overexpressed in various cancers. This technology forms the basis of the company’s lead oncology product candidates, Prostvac and CV-301. Prostvac is an active immunotherapy candidate, currently the subject of a global Phase 3 clinical study “PROSPECT”[7] in men with asymptomatic or minimally symptomatic castration-resistant prostate cancer.
Ebola vaccine development and production
The company has worked for several years with the NIAID[8] on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of the Janssen Pharmaceuticals Companies of Johnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa.[9][10][11] In January 2015, the company had produced the first 400,000 doses of the vaccine and the first clinical trial of the vaccine regimen was initiated in the UK, with additional trials planned in the US and Africa.[12]
Clinical pipeline
Bavarian Nordic's clinical pipeline, as of April 2016.[13]
| Product | Indication | Phase |
|---|---|---|
| Imvanex | smallpox | Approved |
| Prostvac | prostate cancer | III |
| MVA-BN Filo | Ebola and Marburg virus | III |
| CV-301 | bladder cancer | II |
| MVA-BN Brachyury | solid tumors | I |
| MVA-BN RSV | RSV | I |
In addition, the company has multiple pre-clinical projects based on its MVA-BN technology targeting infectious diseases.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
